Pulmonary Diseases
17
1
1
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
12%
2 trials in Phase 3/4
8%
1 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (17)
Use of Anti-CD146 Autoantibodies for the Diagnosis of Pulmonary Diseases Secondary to Occupational Exposure to Silica
Dietitian-supported Meal-ordering and Systematic Nutritional Care
Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology
Specific Genotypes/Phenotypes of Pneumocystis Jirovecii in Solid Organ Transplant Recipients: Potential Involvement of Mycophenolic Acid
Effects of High-Flow Nasal Cannula on Exercise Outcomes in Lung Transplant Candidates: A Pilot Study
Pneumocystis Primary Infection in Non-immunosuppressed Infants
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases
Vibration Response Imaging in the Diagnosis of Pulmonary Disease
Prospective Study on Rehabilitation Patients With Pulmonary Hypertension and Other Pulmonary Diseases
Airways Dysfunction Following WTC Dust Exposure
Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)
Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy
Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)
The Influence of Feeding Position on Pulmonary Morbidity in Young Children
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease